

in association with



society of hematologic oncology

Under the Auspices of

ISTITUTO  
SCIENTIFICO  
ROMAGNO  
PER LO STUDIO E LA CURA  
DEI TUMORI



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Indirizzo: Via dell'Industria, 1 - 40138 Bologna (BO) - Italia  
Telefono: 051/2644411 - Telefax: 051/2644412

# 2 SOHO 2ND ITALIAN CONFERENCE

**Rome - Italy**

**22 › 23 › 24 Sept. 2020**

**A.ROMA Lifestyle Hotel**

**[www.sohoitaly.it](http://www.sohoitaly.it)**

**PRESIDENTS**

**C. Cerchione, G. Martinelli, H Kantarjian**

**SCIENTIFIC BOARD**

**C. Cerchione, N. Daver, C. DiNardo,  
A. Ferrajoli, N. Fowler, G. Garcia-Manero,  
E. Jabbour, H. Kantarjian, H. Lee, T. Kadia,  
M. Konopleva, G. Martinelli,  
G. Musuraca, A. Ravandi, S. Verstovsek**

**JOIN US!**

**[www.sohoitaly.it](http://www.sohoitaly.it)**

**17,5 ECM for:**

**Physicians, Pharmacists, Biologists, Biomedical Laboratory Technicians**

**Organizing secretariat**



**[www.proeventi.it](http://www.proeventi.it)  
[info@proeventi.it](mailto:info@proeventi.it)**

**Follow us SOHOITALY**



**#SOHOITALY20**

# With the patronage of



ALLEANZA  
CONTRO  
IL CANCRO

**SIE**  
Società Italiana di  
Ematologia



Ordine  
Nazionale  
Biologi

®



ONDAZIONE  
ITALIANA  
LINFOMI



istituto  
oncologico  
romagnolo  
*vicine a chi soffri,  
vicine a chi cura*



# MARTINELLI GIOVANNI

As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology “L. & A. Seragnoli”, Azienda Ospedaliera S. Orsola-Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non-positive), and hypereosinophilic syndrome.

# CERCHIONE CLAUDIO

Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassdor of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association

# KANTARIJAN HAGOP M.

Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics

## DAVER NAVAL G.

Dr. Naval Daver is Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Daver received his medical degree at Grant Medical College and Sir J.J. Group of Hospitals, in Mumbai, India. He went on to complete a research fellowship followed by a clinical residency and a clinical fellowship in oncology at Baylor College of Medicine in Houston, Texas. Dr. Daver is board certified in Oncology, Hematology and Internal Medicine. He is a member of the American Society of Clinical Oncology and American Society of Hematology.

## DiNARDO COURTNEY

Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014. The HHMC provides research-based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials. My expertise in myeloid malignancy metabolomics has also driven my research related to therapeutic targeting of glutamine metabolism in myelodysplastic syndrome.

## FERRAJOLI ALESSANDRA

Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals.

She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

## FOWLER NATHAN H.

His interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where he helped to develop some of the first protocols to use lenalidomide in CLL. Since joining the faculty at MD Anderson Cancer Center, the goal of his clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma. He serves as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.

## GARCIA-MANERO GUILLERMO

Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.

## JABBOUR ELIAS

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML.

## LEE HANS C.

Dr. Hans Lee is an oncologist in Houston, Texas and is affiliated with University of Texas MD Anderson Cancer Center. He received his medical degree from Indiana University School of Medicine and has been in practice between 6-10 years.

## KADIA TAPAN M.

Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these..

## KONOPLEVA MARINA

Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs. She has also been an active mentor to trainees including undergraduate, medical and graduate students, post-doctoral fellows who have trained under her direction in support of her various laboratory grants and projects.

# MUSURACA GERARDO

Dr. Musuraca is the Hematology Department Director at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS, in Meldola (FC), Italy.

Since 2001 is involved in multicenter national and international clinical trials performed in onco-hematology (Lymphomas), according to the FDA regulations and/or ICH-GCP guidelines.

Since September 2017, High specialization in Lymphomas. Main fields of research: Chronic Lymphoproliferative Syndromes, Lymphoma, Acute Myeloid Leukemia, Multiple Myeloma, Chronic Myeloproliferative Syndromes, Stem cell transplantation.

# RAVANDI-KASHANI FARHAD

Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

# VERSTOVSEK SRDAN

Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at MD Anderson, he is a global leader in myeloproliferative neoplasms (MPN) and the Founder/Director of the largest MPN Clinical Research Center worldwide.

He has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He is leading pivotal phase 3 trials for several promising myelofibrosis medications.

Dr. Verstovsek received several distinguished awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research (2017) and the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013). He was elected member of The American Society for Clinical Investigation (2015) and received the Celgene 2010 Young Investigator Award for Clinical Research.

DAY 1

22.  
09.  
2020

1 - 4 Sessions

---



# Parallel Lunch Symposium

12.00 - 13.30 · 90 min

## Opening Session

13.30 - 13.40

**Welcome and Introduction What is Italian SOHO**

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian,  
M. Konopleva, G. Martinelli

SESSION

01.

### 1<sup>st</sup> session

## Acute Lymphoblastic Leukemia – State of the art

---

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, M.  
Konopleva, G. Martinelli

13.40 - 13.55

**ALL: State of the art in MD Anderson Cancer Center**

H. Kantarjian

13.55 - 14.10

**ALL: State of the art in Europe**

G. Martinelli

14.10-14.25

**Optimizing adult and Elderly frontline ALL therapy:  
Role of immunochemotherapy**

E. Jabbour

14.25-14.40

**ALL: Ph-like and new genetic subtypes and  
treatment implications**

M. Konopleva

15.00-15.15

**MRD when and how to tailor therapy: role of  
allogenic stem cell transplantation**

A. Rambaldi

SESSION

# 02.

15.15-15.30

**Lecture: Role of NGS in Acute Leukemias**

T. Haferlach

## 2<sup>nd</sup> session

### Acute Lymphoblastic Leukemia – Ph positive ALL

---

M. Konopleva – G. Martinelli

15.30-16.00

**Ph-positive ALL debate:**

15.30-15.45

**Standard chemotherapy-TKI and allo-SCT**

O. Ottmann

15.45-16.00

**How could we potentiate monoclonal  
antibodies' activity?**

R. Foà

16.00-16.15

**Novel TKI and Chemotherapy-free regimens**

S. Chiaretti

16.15-16.30

**CAR T-cells Therapy: Novel generation, Fast-off, Dual CAR T-cells**

J. Ribeira

16.30-16.45

**Novel therapeutic strategies on Acute  
Leukemia based on synthetic lethality**

A. Ghelli

16.45-17.00

**Triple negative B-ALL**

A. Ferrari

SESSION

03.

3<sup>rd</sup> session

## Acute Lymphoblastic Leukemia – Beyond ALL and near future

---

C. Cerchione – H. Kantarjian

17.00-17.15

**Infections in Acute Leukemias**

L. Pagano

17.15-17.30

**Morphology in Acute Leukemias and  
hematologic malignancies**

G. Zini

17.30-17.45

**Monoclonal antibodies: real life and new  
combination trials**

C. Papayannidis

17.45-18.00

**Novel monoclonal antibodies combinations  
and near future of ALL in Italy**

F. Lanza

18.00-18.15

**Future of ALL therapy**

H. Kantarjian

18.15-18.30

**Questions and Answers + Coffee break**

SESSION

04.

## 4<sup>th</sup> session CAR-T session

---

F. Ciceri - F. Locatelli

18.30-18.45

**CAR-T in Europe – State of the art**

F. Locatelli

18.45-19.00

**New CAR-T cell clinical trials for patients with Leukemia or Lymphoma: room for improvement**

C. Quintarelli

19.00-19.15

**Future of CAR-T cells for hematologic and non-hematologic malignancies**

F. Ciceri

19.15 - 19.30

**Questions and Answers**

## Aperitiv Parallel sessions

---

19.30 - 20.30 · 60 min

## Dinner Presidential Symposium

---

21.00

DAY 2

23.  
09.  
2020

5 - 11 Sessions

---

# Meet the experts sessions

---

7.30-8.30

AML: H. Kantarjian/F. Ravandi  
ALL: M. Konopleva/ G. Martinelli  
CML: E. Jabbour/G. Saglio  
CLL: A. Ferrajoli/A. Cuneo  
Immunotherapy: N. Daver/A. Isidori

SESSION

# 05.

## 5<sup>th</sup> session Health Management System

---

M. Altini – F. Falcini

08.30-08.40

**New frontiers in health management**

M. Altini

08.40-08.50

**Role of Oncology registries in Italy:  
Importance for patients and future**

F. Falcini

08.50-09.00

**Clinical Trials Management: present and  
future**

O. Nanni

09.00-09.10

**Multidisciplinary approach in IRST  
OncoHematology Department**

G.L. Frassinetti

09.10-09.20

**Drug Management in Italy: near future  
of Oncopharmacist**

C. Masini

09.20-09.30

**New target therapies in Oncologic  
malignancies**

U. De Giorgi

SESSION

06.

**6<sup>th</sup> session**

**Acute Myeloid Leukemia  
State of the art**

---

H. Kantarjian – F. Ravandi

09.30-09.45

**How I treat AML in MD Anderson Cancer  
Center**

H. Kantarjian

09.45-10.10

**How I treat AML in Europe**

G. Martinelli

10.00-10.15

**How I manage Elderly AML in MD Anderson  
Cancer Center**

T. Kadia

10.15-10.30

**Incorporating novel antibodies as target  
therapies in treatment of older AML**

F. Ravandi

10.30-10.45

**How I manage Elderly AML in Italy**



SESSION

07.

A. Isidori  
10.45-11.00  
**How I manage NPM1 AML**  
B. Falini

11.15-11.30  
**Coffee Break**

## **7<sup>th</sup> session**

# **Acute Myeloid Leukemia**

## **New frontiers**

---

C. Cerchione – G. Martinelli

11.30-11.45  
**Immune based therapies in AML**  
N. Daver

11.45-12.00  
**Frontline fit patients' treatment - 3+7 is not anymore standard of care**  
F. Ferrara

12.00-12.15  
**Targeted therapies in frontline and relapsed AML**  
M.P. Martelli

12.15-12.30  
**Venetoclax based therapies in AML**  
C. DiNardo

SESSION

# 08.

## 8<sup>th</sup> session

### Acute Myeloid Leukemia MRD and Allogenic SCT

---

C. DiNardo - A. Olivieri

12.30-12.45

**Assessment of MRD in AML and integrating MRD into treatment: Role of new techniques**

F. Buccisano

12.45-13.00

**Role of allogenic transplant in novel agents era**

A. Olivieri

13.00-13.15

**Role of postSCT maintenance in AML**

M. Gottardi

13.15-13.30

**Genetic profiling and predicting treatment response in AML**

A. Curti

13.30-14.30

**Lunch symposium sponsorizzato da**

**Jazz Pharmaceuticals extra ECM**

**“CPX-351 in High Risk AML: from bench to bedside”**

**Chair: G. Martinelli**

13.30-13.50

**CPX-351: new advanced liposomal formulation or new drug?**

G. Martinelli

13.50-14.10

**Long-term data from Pivotal Trials**

C. Cerchione

14.10-14.30

**RWE data from international and national experience**

R. Lemoli

SESSION

09.

## 9<sup>th</sup> session

# Acute Myeloid Leukemia Toward individualized treatment

---

C. Mecucci – C. Papayannidis

14.30-14.45

**Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes**

I. Iacobucci

14.45-15.00

**New insights into the biology of acute myeloid leukemia with mutated NPM1**

L. Brunetti

15.00-15.15

**Metabolism in AML**

G. Simonetti

15.15-15.30

**Genetic profiling in novel agents era**

G. Visani

15.30-15.45

**Proapoptotic pathways in AML**

S. Galimberti

SESSION

# 10.

## 10<sup>th</sup> session Acute Myeloid Leukemia Selected populations and new perspectives

---

A. De La Fuente – A. Isidori

15.45-16.00

Environment-mediated drug resistance in  
AML

C. Cerchione

16.00-16.15

Prognostic relevance of a blastic  
plasmacytoid dendritic cell neoplasm-like  
immunophenotype in cytogenetically normal  
acute myeloid leukemia patients

R.M. Lemoli

16.15-16.30

GIMEMA Trials in AML

A. Venditti

16.30-16.45

Clinical Trials in AML: Spanish Experience

A. De La Fuente

16.45-17.00

Questions and Answers AML

17.00-17.20

Coffee break

SESSION

11.

# 11<sup>th</sup> session

## Selected Oral Presentations

---

C. Cerchione – G. Martinelli

17.20-17.30

**Acute Leukemias**

TBD

17.30-17.40

**Lymphomas**

TBD

17.40-17.50

**Multiple Myeloma**

TBD

17.50-18.00

**CML/SMP**

TBD

SESSION

# 12.

## 12<sup>th</sup> session

### Chronic Lymphocytic Leukemia - State of the art

---

A. Cuneo - A. Ferrajoli

18.00-18.15

**How I treat CLL: State of the Art in USA**

A. Ferrajoli

18.15-18.30

**How I treat CLL: State of the Art in Italy**

A. Cuneo

18.30-18.45

**Management of relapsed/refractory disease:  
Novel agents**

P. Ghia

18.45-19.00

**Role of MRD in CLL**

M. Massaia

19.00-19.15

**Biology and management of Richter syndrome**

G. Gaidano

19.15-19.30

**Question and Answers**

## Gala Dinner

21.00

DAY 3

24.  
09.  
2020

13 - 20 Sessions

---

# Meet the experts sessions

---

7.30 - 8.30

MDS: G. Garcia-Manero/V. Santini

MPN: S. Verstovsek/A. Lucchesi

MM: KC Anderson/C. Cerchione

Smoldering MM: M.V. Mateos

NHL: P. Martin/G. Musuraca

HD: N. Fowler/C. Carlo-Stella

SESSION

# 13.

## 13<sup>th</sup> session Multiple Myeloma – State of the art

---

K.C. Anderson - C. Cerchione

08.30-08.45

**Multiple Myeloma: State of the art in Europe**  
C. Cerchione

08.45-09.00

**Multiple Myeloma: State of the art in USA**  
K.C. Anderson

09.00-09.15

**Multiple Myeloma: Trials in MDACC**  
H. Lee

09.15-09.30

**How I manage newly diagnosed  
transplant-eligible MM**  
V. Montefusco

09.30-09.45

**How I treat smoldering MM**  
M.V. Mateos



# 14.

## 14<sup>th</sup> session Multiple Myeloma, Selected populations and new perspectives

---

H. Lee - M.V. Mateos

09.45-10.00

**Role of autologous transplant in MM in novel agents era**

M.T. Petrucci

10.00 - 10.15

**Importance of maintenance**

M. Gentile

10.15-10.30

**How I manage unfit/frail patients**

D. Derudas

10.30-10.45

**Balancing efficacy and tolerability in novel Agents era**

P. Tosi

10.45-11.00

**CAR T-cells therapies in MM**

M. Martino

11.00-11.15

**New drugs on the Horizon**

F. Di Raimondo

11.15-11.20

**Questions and Answers**

11.20-11.30

**Coffee break**

SESSION

# 15.

## 15<sup>th</sup> session Multiple Myeloma – MRD, Biology and near future

N. Bolli - C. Terragna

11.30-11.45

**New insights into biology of MM, SMM and MGUS**

C. Terragna

11.45-12.00

**Importance of imaging in the era of novel agents**

E. Zamagni

12.00-12.15

**New insights in anti-angiogenesis in Multiple Myeloma**

A. Solimando

12.15-12.30

**Genetic profiling of Multiple Myeloma in novel agents era**

N. Bolli

12.30-12.40

**Questions and Answers**

## Lunch parallel symposia

12.40 - 13.40 · 60 min

SESSION

# 16.

## 16<sup>th</sup> session Non Hodgkin Lymphoma State of the art

---

P. Martin - G. Musuraca

13.40 - 14.10


### How I manage DLBCL lymphoma

13.40 - 13.55

in USA 

P. Martin

13.55 - 14.10

in Italy 

G. Musuraca

14.10-14.25

Macrophage oriented prognostication and therapy in  
DLBCL

14.25 - 14.55

### How I manage follicular, mantle cell and marginal lymphoma

---

14.25 - 14.40

in USA 

N. Fowler

14.40 - 14.55

in Italy 

S. Luminari

SESSION

# 17.

## 17<sup>th</sup> session Hodgkin Lymphoma and Biology of lymphomas

E. Derenzini - P.L. Zinzani

14.40 - 14.10


### How I manage Hodgkin disease

14.40 - 14.55

in USA 

J.M. Connors

14.55 - 15.10

in Italy 

C. Carlo-Stella

15.10-15.25

### Microenvironment-driven metabolic rewiring in Lymphomas

A. Romano

15.25-15.40

### Lecture: Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

E. Derenzini

15.40-15.55

### Near future of Non Hodgkin Lymphomas

P.L. Zinzani

15.55-16.10

### Near future of Hodgkin Lymphomas

A. Pinto

16.10-16.20

SESSION

# 18.

## 18<sup>th</sup> session Chronic Myeloid Leukemia

---

E. Jabbour – G. Saglio

16.20-16.35

**How I manage CML in MDACC**

E. Jabbour

16.35-16.50

**How I manage CML in Italy**

G. Saglio

16.50-17.10

**Management of relapsed/refractory CML and advanced phases**

G. Rosti

17.10-17.25

**Treatment-free remission where and when?**

M. Malagola

17.25-17.40

**Near future of treatment free remission in CML**

E. Abbruzzese

17.40-17.55

**European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia**

F. Pane



SESSION

# 19.

## 19<sup>th</sup> session MPN session

---

A. Lucchesi - S. Verstovsek

17.55-18.10

**Updates on the classification of  
myeloproliferative neoplasms**

S. Verstovsek

18.10-18.25

**How I treat Myelofibrosis**

A. Lucchesi

18.25-18.40

**New insights into biology of MPN**

A.R. Migliaccio

18.55-19.10

**Questions and Answers**

# 20.

## 20<sup>th</sup> session Myelodysplastic syndromes: State of the art

---

G. Garcia-Manero - V. Santini

18.40 - 18.55

**Myelodysplastic Syndromes  
State of the art in Europe**

V. Santini

18.55 - 19.10

**Myelodysplastic Syndromes  
State of the art in USA  
Emerging frontline HMA based regimens**

G. Garcia-Manero

19.10-19.25

**Biology and importance of staging systems**

M. Della Porta

19.25 - 19.40

**New combinations for treating Higher-risk  
MDS**

E. Oliva

19.40 - 19.55

**Approach to Management of Lower-risk MDS**

P. Musto

19.55-20.00

**Questions and Answers MDS and MPN**

**Closing remarks and adjour**

C. Cerchione, H. Kantarjian, G. Martinelli



Supported by an unrestricted  
educational grant from

---



Jazz Pharmaceuticals®



BeiGene



astellas



abbvie

AMGEN



neovii



society of hematologic oncology